Mikio Sugimoto - Concepedia

Author

Mikio Sugimoto

Also Known As

Hideo Saito, M Sugimoto, M. Sugimoto, M., Sugimoto, MIKIO SUGIMOTO, Mikio Sugimoto, Nobuo Shinohara, Sugimoto Mikio, The PRIAS-JAPAN study group, Yoshihiro Nishiyama

276

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Kagawa University Tohoku University Kyoto University Harasanshin Hospital Akita University

About

Mikio Sugimoto is an author at Kagawa University specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	26	1.1K
2	Public Health	4	4	74
3	Health Sciences	3	3	101
4	Engineering	1	1	16
5	Biomolecular Engineering	1	1	14

Mikio Sugimoto

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin, NEJM Evidence UrologyGenitourinary CancerMedicineOlaparib ArmPolymerase Inhibitor Olaparib	2022	357
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial Fred Saad, Noel W. Clarke, Mototsugu Oya, The Lancet Oncology UrologyOncologyGenitourinary CancerMedicineAbiraterone Versus Placebo	2023	256
Evidenced‐based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition) Yoshiyuki Kakehi, Mikio Sugimoto, Rikiya Taoka International Journal of Urology	2017	151
Renal cell carcinoma in patients with end‐stage renal disease: relationship between histological type and duration of dialysis Mohammed Ahmed Abdel‐Muneem Nouh, Naoto Kuroda, Motoki Yamashita, British Journal of Urology	2009	102
Expression of Autotaxin and Acylglycerol kinase in prostate cancer: Association with cancer development and progression Mohammed Nouh, Xiu‐Xian Wu, Homare Okazoe, Cancer Science	2009	94
PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Fred Saad, Andrew J. Armstrong, Antoine Thiery-Vuillemin, Journal of Clinical Oncology Androgen ReceptorEndocrine OncologyUrologyOncologyGenitourinary Cancer	2022	80
The impact of baseline [−2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort Hiromi Hirama, Mikio Sugimoto, Kazuto Ito, Journal of Cancer Research and Clinical Oncology	2013	63
Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin, Journal of Clinical Oncology Surgical OncologyClinical EndpointPrognosisPharmacotherapyLogistic Analysis	2023	51
Gene expression profiles of lysophosphatidic acid‐related molecules in the prostate: Relevance to prostate cancer and benign hyperplasia Yu Zeng, Yoshiyuki Kakehi, Mohammed Nouh, The Prostate	2008	47
Differential prognostic factors in low‐ and high‐burden de novo metastatic hormone‐sensitive prostate cancer patients Masaki Shiota, Naoki Terada, Toshihiro Saito, Cancer Science	2020	46

Page 1